Ruifu Lin (瑞复啉)瑞复啉
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 丽珠集团丽珠制药厂Chinese legal name: 丽珠集团丽珠制药厂
主要成分Active Ingredients
- 伊托必利Yituo Bili
药物知识说明
伊托必利是一种在国家药监局注册认定的药品。该药品含有伊托必利-9abf3a27等成分。
该药品关联的活性成分包括：伊托必利Yituo Bili。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：丽珠集团丽珠制药厂Chinese legal name: 丽珠集团丽珠制药厂。
您可以探索含有相同成分的其他药品：伊托必利-9abf3a27成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 瑞复啉) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 伊托必利Yituo Bili.
Manufacturers recorded for this product: 丽珠集团丽珠制药厂Chinese legal name: 丽珠集团丽珠制药厂.
Explore other medicines containing the same ingredient: 伊托必利 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 瑞复啉Recorded Chinese name: 瑞复啉
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 50mg*20片50 mg × 20 tablets
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 丽珠集团丽珠制药厂Chinese legal name: 丽珠集团丽珠制药厂
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20010186
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20010186
Manufacturer
Chinese legal name: 丽珠集团丽珠制药厂 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
50 mg × 20 tablets
中文说明书原文Original Chinese source label
批准文号
国药准字H20010186
生产企业
丽珠集团丽珠制药厂(国产)
适应症
本品为胃肠促动力药，适用于功能性消化不良引越的各种症状，如、上腹不适，餐后饱胀，食欲不不振，恶心，呕吐等。
用法用量
本品成人每次1片，每日3次，饭前服用，根据年龄症状适量酌减。
不良反应
1.过敏症状：皮疹、发热、瘙痒感等。|2.消化系统：腹泻、腹痛、便秘、唾液增加等。|3.精神神经系统：头痛、刺痛、睡眠障碍、眩晕等。|4.血液系统：白细胞减少。确认出现异常时应停止给药。|5.偶尔会出现BUN、肌酐上升，有AST、ALT、催乳素上升(在正常范围内)的报道。|6.其他：胸背部疼痛、疲劳、手指发麻、手抖等。
禁忌
1.对此药物成份过敏者禁用。|2.胃肠道出血、机械梗阻或穿孔时禁用。
注意事项
1.本品可增强乙酰胆碱的作用，故使用时应当注意。|2.使用本品效果不佳时，应避免长期无目的的使用。|3.严重肝肾功能不全者慎用。|4.用药中如出现心电图QTc间期延长者应停药。
贮藏
密封
规格
50mg*20片
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.